Chronic Obstructive Pulmonary Disease Model Development Services
At Ace Therapeutics, we specialize in the design, development, and execution of customized Chronic Obstructive Pulmonary Disease (COPD) animal models to support your COPD studies. We understand that every drug candidate has a unique mechanism of action. Therefore, we do not offer a "one-size-fits-all" model product; instead, we provide flexible, tailored model development services that align precisely with your specific research questions. Our expertise lies in translating your hypotheses into robust, reproducible in vivo data.
COPD is a complex, heterogeneous inflammatory lung condition characterized by progressive airflow limitation, airway remodeling, and emphysema. Developing effective therapeutics requires preclinical models that accurately recapitulate the human disease phenotype.
We utilize several well-established induction methods to model various aspects of COPD pathology. The choice of model depends on your target mechanism, whether it involves inflammation, oxidative stress, protease/antiprotease imbalance, or alveolar destruction.
| Model Type | Induction Method | Primary Research Application |
| Chronic Cigarette Smoke (CS) Exposure | Whole-body or nose-only exposure to mainstream cigarette smoke for several weeks/months. | Evaluating anti-inflammatory drugs, antioxidant therapies, and disease-modifying agents. |
| Elastase-Induced Emphysema | Single or repeated intratracheal/oropharyngeal instillation of elastase. | Screening compounds targeting alveolar repair, matrix remodeling, and protease inhibition. |
| LPS (Lipopolysaccharide) Challenge | Acute or repeated intranasal/oropharyngeal administration of LPS. | Assessing acute anti-inflammatory efficacy and pharmacokinetic/pharmacodynamic (PK/PD) relationships. |
| Combination Models (CS + LPS) | Sequential exposure to LPS and cigarette smoke. | Late-stage efficacy studies for compounds targeting severe, refractory inflammation. |
| Genetic Models (e.g., MMP-12, α1-AT deficiency) | Use of genetically modified mice (available upon request). | Mechanistic studies for specific genetic targets or personalized medicine approaches. |
Once a model is successfully developed and dosed with your test article, our capabilities extend to a full suite of downstream analyses. We help you extract the maximum amount of data from every study.
In-Life Assessments and Pharmacokinetics
Efficacy and Mechanistic Readouts
We provide a multi-parametric analysis to build a comprehensive picture of your compound's effect.
Selecting a CRO partner is a critical decision. We ensure your project is managed with the highest scientific rigor.
Effective COPD therapeutics require models that reflect the disease's complexity. Let us help you build the evidence needed to advance your candidate with confidence.
Can you develop a model that mimics a specific stage of COPD, such as early-stage inflammation versus late-stage emphysema?
Yes. By adjusting the induction protocol (e.g., duration of smoke exposure, dose of elastase), we can tailor the model to represent specific disease stages. We recommend discussing your specific target profile with our scientists to select the optimal model.
What species and strains do you typically use for these models?
While mice (particularly C57BL/6) are the most common due to the availability of reagents and genetic tools, we have experience with rats and guinea pigs where required. The choice depends on the specific readouts (e.g., lung function testing) and the compound availability.
How do you handle test article administration?
We support multiple routes of administration including inhalation (nebulization), intratracheal instillation, oral gavage, intravenous, intraperitoneal, and subcutaneous. The route is selected based on your compound's properties and intended clinical route.
What are the typical sample types you can process from a COPD model study?
We routinely process BALF, serum/plasma, and lung tissues. Lung tissue can be processed for homogenates (biochemistry/ELISA), RNA extraction (qPCR), or fixed for histology/IHC, depending on your endpoints.
Will I receive assistance with interpreting the complex data from these models?
Absolutely. Our engagement goes beyond sample processing. We provide comprehensive data analysis and scientific consultation to help you interpret the results in the context of your drug's mechanism and efficacy profile.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a preclinical research organization focused on respiratory diseases. We provide validated models and rigorous analysis services to support the development of novel therapeutics, from concept to preclinical insight.